339,865 Shares in Vir Biotechnology, Inc. $VIR Bought by Edgestream Partners L.P.

Edgestream Partners L.P. bought a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 339,865 shares of the company’s stock, valued at approximately $3,800,000.

Several other large investors also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Vir Biotechnology in the second quarter valued at approximately $210,712,000. ARCH Venture Management LLC purchased a new stake in shares of Vir Biotechnology in the 2nd quarter worth approximately $129,353,521. ADAR1 Capital Management LLC purchased a new position in Vir Biotechnology during the first quarter valued at approximately $24,593,000. Bank of America Corp DE purchased a new stake in Vir Biotechnology during the second quarter worth $11,642,000. Finally, Avidity Partners Management LP bought a new stake in Vir Biotechnology during the 1st quarter valued at $8,512,000. 65.32% of the stock is owned by institutional investors.

Vir Biotechnology Price Performance

NASDAQ VIR opened at $8.87 on Friday. The stock has a 50-day moving average of $11.00 and a two-hundred day moving average of $9.77. The company has a market cap of $1.52 billion, a P/E ratio of -7.04 and a beta of 1.70. Vir Biotechnology, Inc. has a 1-year low of $5.45 and a 1-year high of $14.38.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.18. The firm had revenue of ($0.19) million for the quarter, compared to analysts’ expectations of $0.98 million. The firm’s quarterly revenue was down 178.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.17) EPS. On average, analysts anticipate that Vir Biotechnology, Inc. will post -1.28 EPS for the current fiscal year.

Analyst Ratings Changes

VIR has been the subject of several analyst reports. Morgan Stanley increased their price objective on Vir Biotechnology from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, November 10th. Zacks Research raised Vir Biotechnology from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 4th. Wall Street Zen raised Vir Biotechnology from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Needham & Company LLC lifted their price objective on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Vir Biotechnology in a report on Monday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.57.

Check Out Our Latest Stock Report on Vir Biotechnology

Insider Buying and Selling

In other Vir Biotechnology news, EVP Vanina de Verneuil sold 2,407 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total transaction of $26,717.70. Following the completion of the sale, the executive vice president owned 110,193 shares of the company’s stock, valued at approximately $1,223,142.30. The trade was a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.90% of the company’s stock.

Vir Biotechnology Profile

(Free Report)

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. Its research draws on immunology and includes approaches such as monoclonal antibodies, small-interfering RNA therapies and T-cell-based treatments. The company’s pipeline has included programs targeting chronic hepatitis B and influenza, as well as investigational cancer therapies. Vir has also pursued research and development collaborations to advance its programs.

See Also

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report).

Institutional Ownership by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.